Louis Garguilo, Chief Editor, Outsourced Pharma has recently published an interview with Ali Pashazadeh, CEO of Treehill Partners, about drug development decision-making and how to improve asset development outcomes for all stakeholders. Surprisingly, decisions are often focused on regulatory approval whilst commercial aspects are not considered. Requirements of financial investors and, ultimately, strategic partners/ buyers rarely form part of drug development strategies. In many cases it is not the molecule that fails to become a commercial success, but the decisions made along its development journey. Click here to read the interview on Outsourced Pharma: https://lnkd.in/eCpq4s5W
Treehill Partners’ Post
More Relevant Posts
-
Really interesting article for International Clinical Trials Awareness Day by Isabel Cameron, BioPharma Reporter, who interviewed our CEO Ali Pashazadeh concerning how #clinicaldevelopment is so often focused on positive outcomes for each phase of a #clinicaltrial, rather than how the therapy will reach a patient in an affordable manner and thus for commercial success. Treehill's extensive research proved only 5% of therapies in #clinicaldevelopment are optimised for commercial viability, and 60% of trials would be rerun by licencing partners. Ali also discusses how Treehill's Clinical Development Optimization model can help bring all those together in the therapeutic development eco-system to increase the chances of therapies to reach patients and the market in a cost effective manner. https://lnkd.in/e7RnR5p5
International clinical trials day: Treehill's quest for commercial and clinical success
biopharma-reporter.com
-
Read on how our CEO Ali Pashazadeh is cited amongst a significant number of KOLs discussing a key issue that is pretty much universally agreed could have considerable long term ramifications to the life science sector. https://lnkd.in/eA7JBmQd
The IRA: A Catalyst for Societal Change | BioSpace
biospace.com
-
Treehill Partners CEO, Ali Pashazadeh, and Fosun Pharma USA Inc. CEO, Rong Yang, will be meeting with potential partners and investors next month at the 42nd J.P. Morgan Healthcare Conference, January 8-11, 2024 in San Francisco, California. Discussions will include the recently announced jointly operating vehicle for investment in high-quality, mid- to late-clinical stage assets. Treehill and Fosun Pharma USA recently extended their partnership to unblock pipelines and will be seeking opportunities in 2024 where a combination of capital, senior leadership involvement and product development acumen will restart the drive of delivery of therapies to patients. Read more within our press release: https://lnkd.in/eyyzCRdg
-
Earlier this week, Fosun Pharma USA and Treehill Partners announced jointly taking a novel path to make capital investments in the US biopharma space, where a combination of capital, senior leadership involvement, and product development acumen will present the key to unlocking value in a short or mid timeframe. https://lnkd.in/esHMPgQr
Fosun, Treehill launch joint investment business to fund drugs angling for US market
fiercebiotech.com
-
Vice President, General Manager Korea at Syneos Health (Previously INC Research/inVentiv Health)
We would be delighted to meet you at 2023 KoNECT International Conference or separately during week of 9-13th October in Seoul for an update about your strategic priorities over the coming 24 months, together with a financial advisory firm, Treehill Partners. We planned this in line with our strong commitment and support for Korea biopharma industry following the successful BIO International Korea event in this June. Please don't miss the opportunity to learn deep insights from our global experts of Syneos Health and Treehill Partners via 1:1 meetings, Luncheon Symposium and Conference sessions! Keith Ruark, Lee Taurman, Ali Pashazadeh, Ken Lee, Keri McDonough, Michael James Ward, Yejee Lee, Hyunseon Kim Syneos Health Treehill Partners KoNECT (Korea National Enterprise for Clinical Trials)
